Creative Touch Permanent Makeup and Aesthetics

Ceramides are the dominant lipid class in the human stratum corneum, comprising approximately 50% of the intercellular lipid matrix that forms the skin’s protective barrier. Working alongside cholesterol and free fatty acids in a physiologically precise ratio, they assemble into stacked lamellar structures between corneocytes, controlling transepidermal water loss, defending against environmental irritants, and maintaining the acidic pH that supports the skin microbiome. What distinguishes ceramides from other moisturising ingredients is their structural specificity: the composition and chain lengths of the ceramide pool, not simply its total volume, determine how well the barrier performs.

A Family, Not a Single Ingredient

The word “ceramide” on a product label covers more than twelve classified subtypes in human skin, each defined by the combination of its sphingoid base and the type of fatty acid attached to it. The two most clinically relevant axes are whether the sphingoid base is sphingosine (S) or phytosphingosine (P), and whether the fatty acid is a standard non-hydroxy chain (N), an alpha-hydroxy chain (A), or an esterified omega-acyl chain (EO). Current INCI nomenclature captures these combinations in two-letter codes: NP, NS, AP, AS, EOS, EOP, and so on. ^[9]

Distinct functional roles map to these structural differences. Ceramides NP and NS are the most abundant subtypes, contributing to lateral lipid packing and direct hydration outcomes. Ceramides EOS and EOP are the acylceramides, making up only around 10% of total ceramides but uniquely responsible for anchoring the long periodicity phase (LPP), the lamellar structure with the tightest waterproofing properties. Ceramide AP contributes primarily to the short periodicity phase (SPP), the complementary lamellar structure that forms throughout the rest of the lipid matrix, and carries anti-inflammatory and filaggrin-supporting properties via its phytosphingosine backbone. A formulation that names specific subtypes can be meaningfully evaluated. One that lists only “ceramides” typically contains a single subtype, most often NP, leaving the LPP-forming and SPP-organising roles entirely unaddressed. ^[5]

How the Skin Makes Ceramides

The skin produces ceramides through three converging pathways, and understanding them explains why ceramide levels can decline even in people without inflammatory skin conditions.

The de novo pathway begins with serine palmitoyltransferase (SPT), the rate-limiting enzyme that combines serine and palmitate to produce the sphingoid backbone from which all ceramide subtypes originate. This is the pathway most directly suppressed by declining oestrogen during perimenopause and by chronically elevated cortisol during psychological stress. Post-menopausal skin shows consistent reductions in ceramide content alongside chain-length shortening, changes that are largely prevented by hormone replacement therapy, pointing to SPT as a key downstream target of oestrogen. ^[10]

The sphingomyelinase pathway converts sphingomyelin, a membrane phospholipid, into ceramide through enzymatic hydrolysis. In post-menopausal skin, elevated sphingomyelin levels alongside reduced ceramides suggest this pathway is also less active than in pre-menopausal skin, compounding the de novo shortfall. The salvage pathway recovers ceramide components from degraded sphingolipids and regenerates usable ceramide without starting from scratch. This route is particularly important for maintaining the ultralong-chain acylceramides EOS and EOP, which require a specialised enzymatic sequence involving ELOVL4 elongase and ceramide synthase CERS3. ^[4]

All three pathways converge in the lamellar bodies of the granular layer, where ceramide precursors are packaged alongside cholesterol and fatty acids for delivery to the extracellular space. Secretion of those lamellar bodies is not automatic – it is triggered by the high- calcium environment of the stratum granulosum, where a precisely maintained calcium gradient peaks to initiate exocytosis. It is this extracellular assembly step, not synthesis alone, that determines whether correct lamellar architecture forms; and it is the calcium gradient, not precursor availability, that controls whether that step is initiated at all.

The Extracellular Processing Step

Ceramide synthesis inside the keratinocyte produces precursors, not the finished barrier lipid. Glucosylceramides and sphingomyelin are the primary forms in which ceramide is packaged into lamellar bodies and secreted into the extracellular space at the stratum granulosum – stratum corneum junction. The conversion to free ceramide that the barrier actually uses happens outside the cell, in the extracellular space, through the enzymatic action of two pH-dependent enzymes secreted alongside the lipid precursors.

β-Glucocerebrosidase (GCase/GBA) converts glucosylceramide to ceramide in the extracellular spaces of the lower stratum corneum. Its pH optimum is approximately 5.2 – and at neutral pH (7.4), activity is essentially absent. GCase activity is highest in the outer stratum granulosum and lower stratum corneum, localised precisely where lamellar body secretion delivers its substrates. ^[8]

Acid sphingomyelinase (aSMase) converts sphingomyelin to ceramide via the sphingomyelinase pathway, with a pH optimum of approximately 4.5. This enzyme’s activity is additionally impaired in atopic dermatitis independently of pH, with reduced aSMase expression found in atopic skin alongside the SPT suppression and ELOVL4 suppression described above. ^[2]

The clinical significance is that both enzymes require the acidic environment that free fatty acids generate. A barrier repair approach that provides ceramide precursors – through diet, supplements, or topical synthesis stimulation – without maintaining the acid mantle conditions these enzymes need will produce incomplete ceramide recovery. The cascade fails at the final conversion step, not from lack of precursor. This is the mechanistic basis for the well-established clinical observation that alkaline cleansers, hard water exposure, and overwashing impair barrier recovery: they neutralise the pH environment that the ceramide-generating enzymes require, halting ceramide production at the last step regardless of synthesis activity upstream.

When Ceramide Levels Fall

Ceramide decline is rarely a single cause but a convergence of factors that compound over time. Ageing reduces overall ceramide synthesis and shortens average ceramide chain length. Shorter chains pack less tightly in the lipid matrix, increasing barrier permeability even when ceramide abundance appears numerically adequate. This chain-length effect helps explain a frustrating clinical pattern: persistent dryness in older clients despite consistent ceramide product use, because the chains in endogenously produced ceramides are no longer generating orthorhombic lateral packing.

In inflammatory skin conditions, the ceramide profile shifts in characteristic ways. In atopic dermatitis, the acylceramide fraction is reduced by approximately 20-50% compared with healthy skin, disrupting LPP formation and increasing transepidermal water loss by 10-33%. Alongside this, the ratio of phytosphingosine ceramides (NP, AP) to sphingosine ceramides (NS) shifts unfavourably. Research replicating the NS:NP ratio found in atopic skin in model membrane systems demonstrated measurably increased TEWL from this ratio shift alone, independent of other lipid changes, confirming that subtype balance rather than total ceramide content determines barrier performance. ^[1]

Cortisol directly suppresses ceramide and cholesterol synthesis, which is why skin reliably deteriorates during high-stress periods. The inflammatory cytokines IL-4 and IL-13, characteristically elevated in atopic conditions, suppress both filaggrin production and ceramide synthesis pathways simultaneously. This creates the barrier-hydration breakdown cycle that is so difficult to interrupt: inflammation suppresses the very lipid production needed for repair.

Evidence for Topical Supplementation

The case for topical ceramides is well established, though the quality of that evidence varies considerably by formulation approach. Single-ceramide products built around Ceramide NP improve hydration measurably and provide a useful baseline for barrier repair. Multi-ceramide formulations that specify acylceramide subtypes alongside cholesterol and free fatty acids in physiological ratios consistently outperform them. Research on ternary NP:cholesterol:fatty acid model membranes at physiological ratios found 38-45% TEWL reduction within 14 days of twice-daily application, confirming the additive benefit of the full lipid triad over ceramide supplementation alone.

Formulation quality materially affects efficacy in ways that total ceramide content on a label does not capture. The ultralong-chain acylceramides EOS and EOP are particularly prone to crystallisation in poorly engineered emulsions, becoming structurally unavailable to the barrier regardless of label concentration. Products that specify individual ceramide types, from formulation-specialist brands that have addressed dispersibility, represent a genuinely different category of barrier repair rather than simply a premium price point. ^[6]

Supporting Ceramide Synthesis from Within

Niacinamide is the topical active with the most direct evidence for supporting endogenous ceramide synthesis, upregulating ceramide, cholesterol, and fatty acid production broadly. In barrier repair protocols, it functions as a useful complement to topical ceramide products rather than an alternative. Used alongside a multi-ceramide moisturiser, it addresses both the supply (topical) and production (synthesis support) sides simultaneously.

The most direct clinical confirmation that pH correction enables ceramide recovery comes from a study of NHE1 activation in mature skin. A clinical trial applying rosmarinic acid cream – an NHE1 activator – to 21 women aged 50–60 found it significantly reduced skin surface pH, increased stratum corneum ceramide content, and improved barrier recovery rate. ^[3] Critically, the ceramide improvement was secondary to pH correction, not the result of any direct ceramide-stimulating activity. This confirms the sequence the entity describes mechanistically: the conversion step fails when the acid environment is absent, and restoring that environment re-enables the processing enzymes already present. For clients with age-related acid mantle decline, supporting NHE1 activity – through topical NHE1 activators or approaches that reduce the alkaline load on the skin – is therefore a legitimate route to ceramide recovery that operates independently of synthesis pathways.

Oral glucosylceramide supplementation has produced clinically meaningful results in randomised controlled research, with hydration improvements of 31.9% at 12 weeks compared with placebo, a finding that the article’s coverage of internal skin support discusses in detail. The mechanism likely involves the salvage pathway, with intestinal-derived ceramide metabolites influencing skin sphingolipid metabolism systemically rather than delivering ceramide directly. Omega-3 fatty acids from fish or algal sources modulate the IL-4 and IL-13 cytokine activity that suppresses ceramide synthesis in atopic and sensitive skin, providing meaningful indirect support.

At Creative Touch

Ceramide depletion underlies a significant proportion of the concerns we address: the perimenopausal client whose skin has become permanently dry, the patient whose barrier has been eroded by enthusiastic exfoliation, the younger client managing long-standing atopic sensitivity. Our approach across all these presentations starts from the same framework: identify which ceramide subtypes are most likely depleted, understand the mechanism driving that depletion, and address it at every practical level simultaneously.

That means guiding clients toward multi-ceramide formulations that specify subtype content, rather than ceramide percentage claims that tell only part of the story. It means incorporating niacinamide as a synthesis-supporting daily active for most repair protocols. It means discussing dietary and supplement routes where appropriate, and considering whether professional treatments offer accelerative benefit. Thulium fractional laser research has found early clinical responders show significant upregulation of lipid metabolism gene expression, including ceramide synthesis pathways, suggesting a route to supporting the barrier from within the tissue rather than supplementing only from the surface.

What we are equally careful about is being honest when topical ceramides alone are insufficient. Lasting barrier improvement typically requires addressing the underlying driver of ceramide depletion, whether that is hormonal, inflammatory, stress-related, or product-driven. The ceramide question in clinic is always: which subtypes are depleted, by what mechanism, and which combination of approaches best matches that specific pattern.

What to Expect

Barrier repair is measured in weeks, not days. Improvements in hydration and reduced TEWL from topical multi-ceramide formulations typically become measurable within two to four weeks of consistent twice-daily use, with maximum response at eight to twelve weeks depending on baseline severity. The lamellar architecture takes time to rebuild, and any active ingredient that disrupts that process, including acids and retinoids used too soon, resets the timeline. For clients with hormonally driven ceramide depletion, topical repair can meaningfully compensate but will require ongoing maintenance rather than a fixed treatment course.